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http://www.biomedcentral.com/1471-2164/13/508RESEARCH ARTICLE Open AccessGenetic structure of community acquired
methicillin-resistant Staphylococcus aureus USA300
Ryan Tewhey1,2,3†, Christopher R Cannavino4,5,6†, John AD Leake4,5, Vikas Bansal1, Eric J Topol1,2, Ali Torkamani1,2,
John S Bradley4,5* and Nicholas J Schork1,2*Abstract
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is a significant bacterial
pathogen that poses considerable clinical and public health challenges. The majority of the CA-MRSA disease
burden consists of skin and soft tissue infections (SSTI) not associated with significant morbidity; however, CA-MRSA
also causes severe, invasive infections resulting in significant morbidity and mortality. The broad range of disease
severity may be influenced by bacterial genetic variation.
Results: We sequenced the complete genomes of 36 CA-MRSA clinical isolates from the predominant North
American community acquired clonal type USA300 (18 SSTI and 18 severe infection-associated isolates). While all
36 isolates shared remarkable genetic similarity, we found greater overall time-dependent sequence diversity
among SSTI isolates. In addition, pathway analysis of non-synonymous variations revealed increased sequence
diversity in the putative virulence genes of SSTI isolates.
Conclusions: Here we report the first whole genome survey of diverse clinical isolates of the USA300 lineage and
describe the evolution of the pathogen over time within a defined geographic area. The results demonstrate the
close relatedness of clinically independent CA-MRSA isolates, which carry implications for understanding CA-MRSA
epidemiology and combating its spread.Background
For the past 75 years, successive waves of antibiotic-
resistant Staphylococcus aureus strains have posed signifi-
cant challenges to clinicians and public health officials [1].
Beta-lactamase-mediated S. aureus resistance developed
within a decade of widespread penicillin use, and two
years after the introduction of methicillin, methicillin-
resistant S. aureus strains (MRSA) appeared. More re-
cently, MRSA has emerged as one of the preeminent
public health threats in the United States and world-
wide. In fact, all-cause S. aureus infections have rapidly
increased during the past decade (1999, 294,570 annual
U.S. cases vs. 2005, 477,927 cases) with MRSA currently
accounting for >50% of staphylococcal disease [2,3].
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reproduction in any medium, provided the orS. aureus than HIV/AIDS [3]. MRSA also represents a
significant economic burden with an estimated annual
U.S. cost of 9 billion dollars [2]. Historically the MRSA
threat consisted of hospital-acquired strains (HA-MRSA)
usually affecting individuals with associated risk factors
(e.g., hospitalization, multiple antibiotics).
Community-associated MRSA strains (CA-MRSA)
have recently emerged as the predominant cause of
MRSA disease [4]. Distinct genetic profiles suggest that
CA-MRSA and HA-MRSA evolved independently. While
methicillin-resistance occurs at a fitness cost to the
organism in HA-MRSA strains, CA-MRSA strains have a
selective advantage and generally affect previously
healthy individuals [5,6]. CA-MRSA strains carry unique
drug resistance genes, and widespread clinical experi-
ence suggests they may possess increased virulence
compared to most HA-MRSA.
While recombination is rare among staphylococci, broad
diversity exists amongst subspecies. Among CA-MRSA
strains, one clonal isolate, USA300, has become pre-
dominant in the United States, representing the majorityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated staphylococcal infection in much of the U.S.
[3,4,7]. Its prevalence is also increasing in Europe [8,9].
USA300’s broad range of clinical manifestations include
asymptomatic colonization, skin and soft tissue infec-
tions (SSTI), and life-threatening, severe disease (e.g.
complicated pneumonia, endocarditis, osteomyelitis, and
other organ-specific pathology) [10]. Given this clinical
diversity, there may exist genetic differences that could
serve as useful predictors of CA-MRSA-related disease
phenotypes or virulence. Classical genotyping method-
ologies such as PFGE and MLST rely on the evaluation
of highly conserved housekeeping genes representative of
the vertical gene pool and resultantly provide insufficient
resolution to predict disease phenotypes. Recent reports
suggest that there are additional genetic components that
contribute to invasiveness not captured by current typing
technologies [11].
In an attempt to understand the population genetic
architecture of CA-MRSA isolates and possibly resolve
genomic differences relating to MRSA invasiveness, we
sequenced the whole genomes of 36 CA-MRSA clinical
isolates. By leveraging novel de novo assembly methods
along with the historical time-stamps associated with the
infections, we sought to determine whether there was
evidence for CA-MRSA selection both across all coding
genes as well as biological pathways implicated to mediate
virulence.
Results
Clinical collection
During 2001–2006, 925 children with MRSA infections
were identified at Rady Children’s Hospital in San Diego,
California. To prevent the inclusion of hospital acquired
strains we excluded 413 isolates (44.6%) (non-sterile
sites, polymicrobial infections, chronic disease requiring
frequent hospitalization, etc.). Among 512 remaining
children, 41 (8%) had severe infections (among whom
36 had viable frozen isolates) and 471 (92%) had SSTI.
36 CA-MRSA SSTI-associated isolates of the same
chronological distribution as that of the severe isolates
were selected for genotypic comparison. The majority of
the clinical diagnoses of the 36 severe CA-MRSA infec-
tions consisted of either osteoarticular infections (52.8%)
or complicated pneumonias (30.6%).
There was no significant difference in patient age,
gender or self-identified ethnicity between the severe
infection and SSTI study groups. Compared with
children with SSTI, children with severe infections had
significantly longer hospital stays, longer duration of
intravenous antibiotic therapy, and total duration of
antibiotics (Additional file 1: Table S1).
Of all children with CA-MRSA severe infections,
3 (8.3%) children died, another 5 (13.9%) requiredintensive care prior to recovery, and 10 others (27.8%)
were hospitalized for ≥ 10 days prior to recovery. Further,
two children (5.6%), both with osteomyelitis, had long-
term sequelae (chronic osteomyelitis and distal radius
growth arrest as documented on follow-up) (Additional
file 1: Table S2 and Additional file 1: Table S3). All
children in the CA-MRSA SSTI group were hospitalized
<10 days and had an uncomplicated recovery during
hospitalization.
Multilocus PCR coupled to electrospray ionization-mass
spectrometry (PCR/ESI-MS) genotyping revealed that all
72 severe infection and SSTI-associated CA-MRSA iso-
lates were of a single genotype: PCR/ESI-MS genotype 1,
which corresponds to PFGE USA300/USA500 and
sequence type 8 designations [12]. We selected 36 iso-
lates representing the entire collection period for whole
genome sequencing (severe infections n = 18; SSTI
n = 18). In addition, two replicate DNA samples from the
USA300 strain FPR3757 (which has a high quality
complete genome in the public database) were sequenced
to serve dual functions of quality control and assistance
during sequence assembly [7].
Sequencing and data summary
We sequenced CA-MRSA isolates using the Illumina
Genome Analyzer II. In order to maximize sequencing
capacity, we sequenced 3 or 4 isolates per lane using
nucleotide barcodes, with an average of 181 Mb of
sequence per isolate. We used a custom pipeline that
leveraged remapping protocols using the aligner BWA
[13] against the closely related reference sequence
USA300-FPR3757 as well as de novo assembly with
Abyss [14] to successfully call polymorphisms ranging
from single nucleotide variants (SNV) to large struc-
tural rearrangements. Of the core genome defined as
the curated FPR3757 sequence, we sequenced to an
average depth of 57-fold with 99.9% of bases across
all genomes covered >5x and 93.8% >20X (Table 1).
In order to prevent false positive calls, we conserva-
tively masked 3% of the genome where placing or assem-
bling short reads could not be confidently performed. All
single nucleotide events as well as large insertions and
deletions that originated in the masked region were dis-
carded. We also detected the presence of all four previ-
ously identified USA300 plasmids in our isolates. The
most common combination was the presence of pUSA01
and pUSAHOU300 in 22 of the isolates (Figure 1). The
remaining 14 strains represented an additional 4 com-
binations that is not delineated by the phylogenetic
structure of the population. As noted, in addition to
the 36 clinical CA-MRSA isolates, we sequenced the
FPR3757 reference strain in duplicate. Perfect concor-
dance was obtained between the duplicates with each
sample having 24 detected variants compared to the
Table 1 Sequencing Summary
All variants Large events (>100 bp)
Deletions Insertions
Sequenced Nonubiquotus Sequence Mapped Additional Sequence
Bases (Mb) Coverage SNV SNV Deletions Insertions Total Events Size Events Contigs Size
FPR3757 r1 155.74 56 19 - 4 1 24 0 - 0 0 -
FPR3757 r2 148.06 53 19 - 4 1 24 0 - 0 0 -
RCH_I15 164.67 59 59 35 5 2 66 0 - 0 0 -
RCH_I18 199.24 71 64 40 5 4 73 2 35.6 kb 0 0 -
RCH_I19 190.7 68 66 42 5 1 72 0 - 1 2 43.9 kb
RCH_I21 188.24 67 61 39 6 4 71 1 14 kb 0 0 -
RCH_I29 203.32 73 60 36 6 3 69 1 101 bp 1 3 41.1 kb
RCH_I33 122.77 44 59 35 6 3 68 0 - 0 1 1.8 kb
RCH_I34 168.63 60 69 45 6 3 78 0 - 0 0 -
RCH_I35 222.67 80 55 31 4 2 61 0 - 0 0 -
RCH_I36 155.12 55 79 55 11 5 95 0 - 0 0 -
RCH_I38 217.8 78 65 41 7 4 76 0 - 0 0 -
RCH_I42 125.61 45 70 46 6 7 83 0 - 0 0 -
RCH_I44 176.91 63 102 78 6 4 112 1 15.1 kb 0 0 -
RCH_I48 245.34 88 77 53 6 5 88 0 - 0 0 -
RCH_I49 191.01 68 71 47 9 3 83 0 - 0 0 -
RCH_I56 109.38 39 173A 149 9 4 186 0 - 1 7 43 kb
RCH_I57 126.2 45 72 48 7 3 82 0 - 2 18 73.6 kb
RCH_I58 189.15 68 71 47 6 2 79 0 - 1 1 44.2 kb
RCH_I59 180.82 65 82 58 6 6 94 1 144 bp 0 0 -
RCH_S15 181.39 65 52 28 5 1 58 1 457 bp 0 0 -
RCH_S18 121.72 43 66 42 5 2 73 0 - 0 0 -
RCH_S20 129.55 46 64 40 7 4 75 0 - 0 3 21.1 kb
RCH_S21 215.48 77 64 40 10 2 76 0 - 1 5 43.4 kb
RCH_S29 169.87 61 76 52 8 2 86 0 - 1 1 42.4 kb
RCH_S33 159.97 57 112 88 11 5 128 0 - 0 0 -
RCH_S34 207.21 74 76 52 7 3 86 1 4.2 kb 0 0 -
RCH_S35 195.87 70 61 37 4 2 67 1 - 0 0 -
RCH_S36 205.53 73 75 51 5 1 81 0 3.8 kb 1 0 44.3 kb
RCH_S38 179.7 64 89 65 7 3 99 1 766 bp 1 0 4.6 kb
RCH_S43 147.2 53 88 64 11 3 102 1 14 kb 0 0 -
RCH_S44 233.41 83 90 66 11 3 104 0 - 1 0 42.1 kb
RCH_S47 211.06 75 89 65 11 2 102 0 - 0 0 -
RCH_S49 197.15 70 68 44 4 2 74 0 - 0 0 -
RCH_S56 170.35 61 96 72 8 5 109 0 - 0 0 -
RCH_S57 185.6 66 76 52 7 3 86 0 - 1 0 42.9 kb
RCH_S59 229.36 82 86 62 9 6 101 0 - 2 2 81.9 kb
RCH_S60 202.12 72 117 93 11 2 130 1 14 kb 0 1 35.5 kb
A - 84 SNV & 1 insertion confined to a single 10 kb stretch were removed from all subsequent analysis.
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reported as probable errors in the reference sequence [15].
We identified 7 new variants in FPR3757, 5 of which
were seen in all clinical isolates, supporting their status
of true variants. The remaining two variants werevisually inspected and determined as true variants. We
also detected one large rearrangement in the refer-
ence sequence consisting of a 13.3 kb relocation. This
rearrangement had been previously reported in a sepa-
rate USA300 strain [15] and was also detected in all
Figure 1 Table exhibiting homoplasy of large insertion/deletion
events. The first 8 columns represent elements previously reported
in USA300 isolates. The last 4 columns represent phage insertion
sites discovered in our dataset (number denotes position in
FPR3757). P and A represent presence or absence of the site
respectively. The P/A for RCH I18 is a 21.6 kb deletion overlapping
both the mec and ACME region but not entirely deleting either site.
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and presume it to be an error in the original assembly of
the FPR3757 reference sequence.
With respect to the clinical CA-MRSA isolates, the
severe and SSTI groups each carried a mean of 71 and
80 single nucleotide variants (SNV), respectively (p= 0.03,
Analysis of Covariance with time as a covariate) (Table 1,
Additional file 2: Figure S1). Of the 1054 SNV sites,
88% were private to a single isolate with 94% occur-
ring at an allele frequency of less than 10% (3 or
fewer isolates). We performed multiple sequence
alignment on all 36 isolates as well as the resequenced
FPR3757 strain and constructed a maximum-likelihood
phylogenetic tree (Figure 2). There is no obvious differ-
entiation between severe and SSTI isolates with respect
to their placements on the tree. However, there are twodistinct haplogroups defined by 5 variants distributed
across the genome. This suggests a decisive split in the
lineage of the isolates from an ancestral clone. We
screened our entire collection of severe (n = 36) and SSTI
(n = 36) isolates for one of the eight haplogroup-defining
variants and saw a modest association between the
more recently arisen haplogroup B with the less severe
(SSTI) isolates (OR= 2.89, 95% CI 1.2-7.0, p = 0.03).
In both groups we observed a distinct temporal correl-
ation supporting that the isolates are evolving away from
a single common clone over time. We estimated an aver-
age mutation rate of 1.7×10-6 (95% confidence interval,
4.5×10-7 to 2.9×10-6) per site per year for severe isolates
and 2.6×10-6 (95% confidence interval, 9.1×10-7 to
4.3×10-6) per site per year for SSTI isolates (Figure 3).
These values are in close concordance with a previously
reported estimate of 3.3×10-6 per site per year in hospital-
acquired S. aureus [16]. Among SNVs, there was a transi-
tion: transversion ratio of 1.6:1 and a higher frequency of
[ACGT]- > [AT] mutations, with a 1.9 fold greater occur-
rence, suggesting that CA-MRSA is actively introducing
additional AT bias in an already GC depleted genome
(Additional file 1: Table S4).
Small deletions (<100 bp) were 2-fold more frequent
than small insertions (<100 bp) among the 36 clinical
isolates. As expected, we found that indels were most
likely to occur in homopolymer stretches, consistent with
polymerase slippage during replication [17]. Large dele-
tions were detected in ten of the isolates. The largest
deletion (21.6 kb), observed in a severe isolate, included a
large portion of both the SCCmec and ACME regions
but retained pbp2 (the gene responsible for methicillin
resistance). The ACME region has previously been pos-
tulated to be one of the loci responsible for USA 300’s
increased pathogenicity. While this locus may play a role
in pathogenicity, our data suggest that the entire ACME
region may not be required for severe infection. There
was also a common 14 kb deletion completely removing
staphylococcal pathogenicity island SaPI5 observed in
2 severe and 2 SSTI isolates. The deletion appeared on
three separate bootstrapped supported branches of the
phylogenetic tree, suggesting either recombination or
three independent deletion events.
Large insertions (>100 bp) and additional contigs
accounted for 606 kb of novel sequence across 15 isolates
(6 severe and 9 SSTI isolates). For 12 isolates, we placed
14 insertions onto the core genome consisting of 269 kb of
the additional sequence. Of the 14 placed insertions, 11 are
large mobile genetic elements (MGEs) of prophage origin.
There were four unique insertion sites for the 11 MGEs
observed: 2 private appearing in only one isolate
sequenced, 1 site shared by two isolates, and 1 site found in
seven isolates at position 2.01 Mb on the reference
sequence (Figure 1).
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Figure 2 Maximum likelihood phylogenetic tree of the 36 clinical CA-MRSA isolates and the reference strain USA300-FPR3757. 100
bootstraps were performed and branches that carried 95% support are starred. The tree was constructed from a 2872943 bp alignment with 126
informative sites. The severe isolate designated RCH_I56 is truncated and the size of the truncation is listed on the tree.
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2.01 Mb the phylogenetic reconstruction suggests only
two isolates share the insertion due to a single common
ancestor with the remainder representing independent
events. This insertion and the previously discussed 14 kb
deletion represented two of the 11 events we detected as
exhibiting homoplasy within our data (Additional file 1:
Table S5). Unlike previous observations, we did not
observe any convergent events with obvious implications
for drug resistance [16]. This is not surprising in light
of the fact that prior studies characterized HA-MRSA
isolates that are presumably under different selective
pressures than our pediatric CA-MRSA isolates from
previously well children. Of the 9 SNVs exhibiting homo-
plasy, only three affected protein-coding sequence
directly. However, 4 of the 9 SNVs fell within or directlyadjacent to transcriptional regulators, or within putative
regulatory binding sequence. This suggests that regula-
tory mechanisms may play an equally critical role in
CA-MRSA pathogenesis as point mutations conferring
functional protein-coding changes.
Functional distribution of mutations
To assess the distribution of functional differences in
our collection we annotated all non-ubiquitous va-
riants of 100 bp or smaller into three distinct classes:
non-synonymous coding, synonymous coding, non-
coding (Additional file 1: Table S6). In line with our dis-
covery of a greater overall abundance of variants in the
SSTI isolates we saw a significantly larger number of
both synonymous and non-coding variants in the SSTI
isolates when compared to the severe isolates. For
Figure 3 Assessment of both total and genic mutations of the 36 clinical CA-MRSA isolates. Number of total (a), noncoding (b)
synonymous (c) and nonsynonymous (d) mutations in each of the isolates for the severe (red) and SSTI (blue) isolates are shown. Isolates are
plotted according to their date of collection with the earliest isolate signifying month 1.
Tewhey et al. BMC Genomics 2012, 13:508 Page 6 of 11
http://www.biomedcentral.com/1471-2164/13/508synonymous changes there were 219 variants in the SSTI
isolates compared to 149 in the severe isolates (p = 0.003,
Analysis of Covariance with time as a covariate). For
non-coding changes we detected 434 changes in SSTI
and 387 in the severe isolates (p = 0.08). For non-
synonymous variants the trend was similar with an over
abundance of variants in the SSTI isolates (SSTI = 522,
severe = 455) although this difference did not pass our
threshold for significance (p = 0.16). The higher propor-
tion of synonymous variants in the SSTI isolates rela-
tive to the difference in non-synonymous variants did
create an overall lower dN/dS ratio in our SSTI isolates
(student’s t-test, p = 0.04). However, we are cautious of
any classical interpretation of the dN/dS given the highly
clonal nature of the samples and the small population
size; both of which have been shown to cause fluctuation
in the dN/dS calculations [18,19].
Pathway analysis
Under the hypothesis that the SSTI isolates are evolving
away from a virulent phenotype we looked for an enrich-
ment of genes harboring unique nonsense, ns-cSNVs or
deleterious frame shift mutations among the SSTI iso-
lates in genes related to virulence. Since no single gene
harbored enough variants across sufficient number of
isolates for direct testing, we sought to determine if
there was enrichment across all virulence-associated
genes classified as being involved in “pathogenesis” or
“toxin production and resistance” by the JCVI CMR data-
base [20]. This list consisted of 94 genes encompassing
4.9% of the total coding genome. We tested against only
private variation among the isolates to prevent overt biasfrom the few mutations that are shared. There were 335
putative functional variants found in the SSTI isolates
with 27 in genes related to virulence (Table 2). This
represents a 1.66 fold increase over the expected value if
the placement of variation was random across the
genome (binomial test p <0.01). In contrast the severe
isolates carried close to the expected number at 13 va-
riants out of 281, although we cannot claim a difference
between the two groups given the number of isolates
sampled (Chi squared of Invasive vs SSTI: p = 0.1).
Discussion
To address a major public health crisis that involves
an infectious disease, it is essential that we track and
better understand the biology of the causative pathogen.
High-throughput DNA sequencing technologies provide
a platform for tracking pathogens as they propagate
and permit insights into virulence determinants which
could be targeted pharmacologically. We sequenced the
complete genomes of 36 emerging CA-MRSA isolates,
half of which caused lethal or severe infections. As
expected, we found evidence that all isolates of CA-MRSA
are accumulating genetic variation over time, indicative
of an evolution away from an ancestral clone. This rate
corresponded to what has been seen in a similar study
for HA-MRSA suggesting that, at least at a population
wide level, these two distinct classes are evolving at a
similar rate [16]. However at higher resolution these
two groups likely have distinct pressures being applied
to them given their differing environments. One such
example is the lack of homoplasy within genes related
to antimicrobial resistance. In addition we did not
Table 2 Variants in virulence related genes
Gene Gene ID Position Ref base Alt base Substitution Invasive SSTI
immunoglobulin G binding protein A precursor SAUSA300_0113 128554 G T N380K 0 1
IucC family siderophore biosynthesis protein SAUSA300_0123 142320 G T S404I 1 0
sucrose-specific PTS tranporter protein SAUSA300_0194 226384 C T A153V 1 0
sucrose-specific PTS tranporter protein SAUSA300_0194 226642 G A G239D 0 1
choloylglycine hydrolase family protein SAUSA300_0269 321604 C A P194T 0 1
essC protein SAUSA300_0283 336391 G A E142K 0 1
essC protein SAUSA300_0283 336694 A G I243V 1 0
superantigen-like protein 5 SAUSA300_0399 451121 C A A7E 1 1
superantigen-like protein SAUSA300_0407 460962 TACAG ——— Frameshift 108 11 10
dimethyladenosine transferase SAUSA300_0470 530052 T A V258E 0 1
clumping factor A SAUSA300_0772 859497 C A A117D 0 1
enterotoxin Q SAUSA300_0801 884359 T - Frameshift 142 1 0
cysteine protease precursor SAUSA300_0950 1038844 A T V206E 0 1
fmt protein SAUSA300_0959 1051797 C T T269I 0 1
alpha-hemolysin precursor SAUSA300_1058 1157169 G T T53N 0 1
putative fibronectin/fibrinogen binding protein SAUSA300_1101 1204860 C A D555Y 0 2
putative enterotoxin type A SAUSA300_1559 1708640 C A E78* 1 0
cell wall surface anchor family protein SAUSA300_1702 1878567 G A P1968S 1 0
cell wall surface anchor family protein SAUSA300_1702 1878783 G C Q1896E 0 1
cell wall surface anchor family protein SAUSA300_1702 1878930 C A A1847S 0 1
cell wall surface anchor family protein SAUSA300_1702 1880436 C T E1345K 0 1
cell wall surface anchor family protein SAUSA300_1702 1880783 G A A1229V 0 1
serine protease SplA SAUSA300_1758 1943333 T C D113G 0 1
lantibiotic epidermin biosynthesis protein EpiC SAUSA300_1765 1950378 A G V209A 0 1
lantibiotic epidermin biosynthesis protein EpiB SAUSA300_1766 1953206 T - Frameshift 261 0 1
leukotoxin LukD SAUSA300_1768 1955543 C T V254I 1 0
leukotoxin LukE SAUSA300_1769 1957230 T C K4E 0 1
Aerolysin/leukocidin family protein SAUSA300_1975 2130674 G A A63V 1 0
Aerolysin/leukocidin family protein SAUSA300_1975 2130847 T - Frameshift 5 0 1
hyaluronate lyase precursor SAUSA300_2161 2338286 G T K65N 0 1
hyaluronate lyase precursor SAUSA300_2161 2340008 A T L639F 1 0
AcrB/AcrD/AcrF family protein SAUSA300_2213 2380381 - T Frameshift 1050 0 1
AcrB/AcrD/AcrF family protein SAUSA300_2213 2382879 A T L218* 0 1
teicoplanin resistance associated membrane
protein TcaB protein
SAUSA300_2301 2473522 C G W311C 0 1
IgG-binding protein SBI SAUSA300_2364 2540728 G A E150K 0 1
IgG-binding protein SBI SAUSA300_2364 2540773 C A Q165K 1 0
IgG-binding protein SBI SAUSA300_2364 2540911 G A V211M 1 1
gamma-hemolysin component A SAUSA300_2365 2542364 C A Q80K 1 0
gamma-hemolysin component C SAUSA300_2366 2543638 A G I6V 0 1
putative transporter SAUSA300_2406 2591556 A C M273R 2 0
clumping factor B SAUSA300_2565 2774393 C T G883R 0 1
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and non-core portions of the genome as previously
reported [21]. However, given the different population
of samples and the smaller sample set that our datarepresents, neither discordance is troubling. We did de-
tect that the accumulated genetic variation appears to be
higher among CA-MRSA isolates causing the milder
SSTI phenotypes. This distance also manifested itself by
Tewhey et al. BMC Genomics 2012, 13:508 Page 8 of 11
http://www.biomedcentral.com/1471-2164/13/508association of a distinct haplogroup, which evolved from
the parental strain, with the less severe sample. Further,
pathways involved in virulence are enriched among genes
harboring coding variations among the clinical isolates of
lesser clinical severity. Taken together, these data suggest
that the invasiveness of USA 300 may be dependent, to
some degree, on the genetic distance a particular clone is
away from the clonal parental USA 300 strain. USA 300
was first described a little over a decade ago suggesting
its emergence is recent [22,23]. The strain is a result of a
two step process; first through the acquisition of the
SCCmex IV complex which resulted in the clonal type
USA500, followed later by the acquisition of several
genes including the PVL and ACME loci [24]. Given that
Staphylococcus aureus is a natural member of our nasal
flora, as demonstrated by pervasive asymptomatic car-
riage [25,26], there is likely genetic pressure on the
organism to maintain some degree of a commensal
relationship and as a result dampen the hyper-virulent
characteristic which arose from a single recombination
event. This “wave” of clonality wherein an epidemic clone
decreases it pathogenicity and as a result its association
with infections independent of control measures has
been seen in other MRSA strains [27]. Thus, the increase
in genetic diversity of USA300 SSTI isolates may be an
evolutionary progression away from being the hyper-
virulent clonal type that USA300 represents.
The fact that we did not find any single genetic variant
or set of genetic variants readily capable of distingui-
shing severe- and SSTI associated CA-MRSA isolates
speaks to the complexity of MRSA pathogenicity and
underscores the need for more sophisticated ways to
identify disease-causing CA-MRSA strains via genomic
screens. While we focused our analysis to only a small
number of CA-MRSA isolates displaying distinct clinical
phenotypes, we are optimistic that surveying a large
number of isolates (including CA-MRSA asymptomatic
carrier- and MSSA-assocaited isolates) in the future will
provide the power to detect evolutionary pressures at the
single gene level. Of course there are two genomes at
play during an infection and, as a result, a greater under-
standing of human genetic variation is also pivotal for
the complete picture of how genetic architecture influ-
ences our interaction with microbial pathogens. It is
also important to recognize that numerous non-genetic
influences for virulence exist; as such to effectively in-
vestigate the genetics of pathogenicity it is critical to
properly select the cases as to mitigate such effects of
predisposition.
Conclusions
Technological advances and continued decreases in the
cost of sequencing are allowing the whole genome re-
construction of large collections of pathogens. Thesedata sets offer valuable insight into the clonal population
structure as well clues into the evolutionary pressures
applied to the pathogen and will provide a foundation
for the use of whole genome sequencing in a clinical set-
ting. In the future, the genomic identity of individual
isolates may be increasingly compared to global patho-
gen databases allowing the rapid identification of strains
likely to cause severe disease, possess drug-resistance,
and additional traits of critical utility to inform clinical
decisions.
Methods
Isolate selection
For the five year period from January 1, 2003 to December
31, 2007, we identified two sets of children infected by
CA-MRSA: (1) those with severe infections and (2) those
with SSTI. Severe infections were defined as those caus-
ing invasive, potentially life-threatening clinical disease,
including: complicated pneumonia (necrosis, empyema,
or lung abscess); endocarditis (defined as persistent
bacteremia with echocardiographic findings); deep tissue
invasive abscess (mediastial, perinephric); osteoarticular
infection; and pyomyositis (Additional file 1: Table S2).
SSTI were defined as soft-tissue abscesses not associated
with severe disease (as above) but requiring incision and
drainage.To populate these two study groups, sterile-site
(blood, bone, joint fluid, tracheal aspirate, pleural fluid,
invasive abscess, soft-tissue abscess) MRSA isolates
obtained from individual, healthy children aged 0–18
years were included. Non-sterile site (e.g. nasopharynx,
stool) and polymicrobial infections were excluded. Iso-
lates obtained from children with chronic diseases or
immunocompromised states (diabetes, cystic fibrosis,
neoplasm, etc.), from vascular catheters or catheter-sites
and nosocomial isolates (onset after hospital admission)
were also excluded.
Demographic and clinical data
Clinical and laboratory data for all patients were
collected on a standardized data collection form in-
cluding: age; gender; self-identified ethnicity; infection
site; length of stay (including pediatric intensive care
unit stay); inpatient and discharge antibiotic treat-
ment regimen and duration; outcome; and long-term
sequelae (Additional file 1: Table S1).
Specimen processing
Frozen MRSA specimens were thawed and inoculated
onto blood-agar plates with two rounds of subculturing
to ensure optimal growth. Colonies were then transferred
into enriched brain/heart infusion broth media. DNA ex-
traction was performed using a with DNeasy blood and
tissue kits with lysostaphin replacing lysozyme during
the initial lysis. (Qiagen, Germantown, MD).
Tewhey et al. BMC Genomics 2012, 13:508 Page 9 of 11
http://www.biomedcentral.com/1471-2164/13/508Illumina sequencing and preparation
For each of the 36 samples Illumina library preperation
started with 5 ug of extracted DNA quantified by 260/
280 (nanodrop). The standard Illumina protocol was
followed through using reagents from New England
Biosciences with the following exceptions: samples were
sheared by either nebulization or adaptive focused acous-
tics (Covaris), sequencing adaptors added after a-tailing
contained an addition 4 bp nucleotide barcode on the
3’ end allowing for the multiplexing of up to 4 samples
per lane. After library preparation paired-end sequencing
was performed for 40 cycles on each read and images
were processed using Illumina pipeline 1.4. Data for each
isolate can be accessed at http://sites.google.com/site/
ryantewhey/home/data.
Sequence assembly
Genome assembly utilized a mapping/denovo hybrid
approach consisting of the following; Reads were first
mapped using BWA [13] and default parameters to
the reference FPR3757 core genome its three plasmids
and the pHOU300 plasmid. Plasmids with little or no
coverage were discarded. Variants and small indels with a
BWA consensus score of 30 or greater and a mapping
score of 10 or greater were incorporated into the se-
quence. We also utilized custom variant calling pipelines
for further refinement of insertion/deletion detection.
Mapping quality was then assessed across the genome
and detected plasmids. The genome was then broken
into ‘mapping contigs’ where paired-end information was
discordance (outside the expected size distribution),
mapping quality was high and spanning coverage was
low. Separately reads were processed using the Abyss
[14] assembly package using default parameters and a
kmer of 23. Only assembled contigs of 1000 bp or greater
were used for subsequent analysis.
Using a combination of BLAT [28] and the AMOS as-
sembly package (http://amos.sourceforge.net), mapping
and de novo contigs were merged to produce a consensus
contig. In instances were the mapping and denovo contigs
differed two separate contigs were produced. Reads were
then mapped over the two assemblies (mapping consensus
& denovo consensus) separately with BWA allowing only
perfect matches. The location was then assessed at both
variants for mapping quality and the variant with the great-
est support via mapping was chosen.
Contigs were then scaffolded using the FPR3757 refer-
ence genome and multiple alignment was performed
using the progressive Mauve engine of Mauve [29] fol-
lowed by visual inspection and realignment.
Sequence analysis
Prior to creating a phylogenetic tree all insertions and
deletions were removed from the sequence and recodedas a single nucleotide transversion polyphorphism at the
site of the event. A maximum likelihood tree was then
constructed using RAxML [30] with 100 bootstraps on
the CIPRES portal (http://www.phylo.org/). The tree was
visualized and rooted using FigTree software (http://tree.
bio.ed.ac.uk/software/figtree/).
For all variant analysis 24 variants were seen in all 36
clinical isolates and were removed from all subsequent
analysis. In addition, 84 single nucleotide variants and 1
insertion were found clustered together within a 10 kb
window of isolate I56. These variants most likely repre-
sent a single event such as recombination and not mul-
tiple unique events. Because of this they were removed
from all variant analysis.
For the calculation of the dN/dS ratio we used the
formula (N/n)/(S/s), where N and S are the number of
nonsynonymous and synonymous mutations respectively
found in the sequenced isolates, n is the total possible
nonsynonymous mutations and s is the total number of
possible synonymous mutations in the FPR3757 core
genome. Significance of selection between groups of iso-
lates was calculated with a two-tailed t-test. Mutation
rate differences between the two isolate groups were
calculated from the interaction effects of a standard
linear regression. Correlation within strains to syn-
onymous, nonsynonymous and noncoding mutations
were calculated from Spearman’s non-parametric correl-
ation coefficient.
Primary and secondary gene role categories were
assigned to genes based on the J. Craig Venter Institute
Comprehensive Microbial Resource annotation of
Staphylococcus aureus USA300-FPR3757. Enrichment
probabilities were calculated based on the binomial dis-
tribution, where the observed number nonsynonymous,
nonsense, and frameshift mutations within a pathway
was compared to the expectation due to random chance.
The expected proportion of mutations occurring within
a pathway is defined as the sum of the lengths of the
genes belonging to the pathway over the sum of the
length of all genes within the Staphylococcus aureus
USA300-FPR3757 genome. Regions of the genome
masked out during the sequence assembly and variant
calling phases were not included in the pathway or
whole genome summations.
Haplotype genotyping
To genotype the larger collections of 36 severe and 36
SSTI isolates we tested one of the eight variants that
differentiated between the two haplogroups. Standard
PCR was performed for 35 cycles with Phusion mastermix
(Finnzymes) and 100 nM of Primer A (GCAGCAATAC
CACCGAAAAT) and Primer B (GCGCAAGCTAGTGG
GATAAG). PCR products were purified with Agencourt
AMPure beads (Beckman Coulter Genomics) and
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overnight at 37 C. The genotype was then visually scored
on a agarose gel with the uncut product corresponding
to haplotype A of the reference strain FPR3757.
Additional files
Additional file 1: Table S1. Patient characteristics of sequence isolates
by study group. Table S2: Clinical diagnoses of included CA-MRSA severe
infections. Table S3: Site of included CA-MRSA severe infections. Table
S4: Nucleotide mutation catagories. Table S5: Variants exhibiting
convergent evolution. Table S6: Protein Altering Single Nucleotide
Variants.
Additional file 2: Figure S1. Pangenomic representation of all 36
clinical isolates relative to the USA300 FPR3757 reference.
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